

CHAPTER 4(D)

Health certificate

For treated blood products, excluding of equidae, for the manufacture of derived products for purposes outside the feed chain for farmed animals, intended for dispatch to or for transit through<sup>2</sup> the European Union

COUNTRY: UNITED STATES

Veterinary certificate to EU

Part I : Details of dispatched consignment	I.1. Consignor Name Address		I.2. Certificate reference No		I.2.a.	
	Tel.		I.3. Central competent authority <b>APHIS-VS</b>			
	I.5. Consignee Name Address  Postal code Tel.		I.4. Local competent authority			
	I.6. Person responsible for the load in EU Name Address  Postal code Tel.					
	I.7. Country of origin					
	Code		I.9. Country of destination		ISO code	
	I.10. Region of destination		Code			
	I.11. Place of origin  Name Approval number Address		I.12. Place of destination  Name Address Postal code			
	Name Approval number Address		Custom warehouse <input type="checkbox"/> Approval number			
	Name Approval number Address					
I.13. Place of loading		I.14. Date of departure				
I.15. Means of transport  Aeroplane <input type="checkbox"/> Ship <input type="checkbox"/> Railway wagon <input type="checkbox"/> Road vehicle <input type="checkbox"/> Other <input type="checkbox"/>		I.16. Entry BIP in EU				
Identification		I.17.				
Documentation references						
I.18. Description of commodity		I.19. Commodity code (HS code) <b>30.02</b>				
		I.20. Quantity				
I.21. Temperature of product  Ambient <input type="checkbox"/> Chilled <input type="checkbox"/> Frozen <input type="checkbox"/>		I.22. Number of packages				



Part II: Certification	<b>II. Health information</b>	II.a. Certificate reference No	II.b.
	<p>I, the undersigned official veterinarian, declare that I have read and understood Regulation (EC) No 1069/2009 of the European Parliament and of the Council<sup>(1a)</sup> and in particular Article 8(c) and Article 8(d) and Article 10 thereof, and Commission Regulation (EU) No 142/2011<sup>(1b)</sup>, and in particular Annex XIV, Chapter II thereof, and certify that:</p>		
	II.1.	the blood products described above consist of blood products that satisfy the requirements below;	
	II.2.	they consist exclusively of blood products not intended for human or animal consumption;	
	II.3.	they have been prepared and stored in a plant supervised by the competent authority exclusively with the following animal by-products:	
		<sup>(2)</sup> either <del>[- blood of slaughtered animals, which is fit for human consumption in accordance with Union legislation, but is not intended for human consumption for commercial reasons;]</del>	
		<sup>(2)</sup> and/or [- blood of slaughtered animals, which is rejected as unfit for human consumption in accordance with Union legislation, but which did not show any signs of diseases communicable to humans or animals, derived from carcasses that have been slaughtered in a slaughterhouse and were considered fit for human consumption following an ante-mortem inspection in accordance with Union legislation;]	
		<del><sup>(2)</sup>and/or [- blood of slaughtered animals, which did not show any signs of diseases communicable to humans or animals, obtained from animals other than ruminants that have been slaughtered in a slaughterhouse after having been considered fit for human consumption following an ante-mortem inspection in accordance with Union legislation;]</del>	
		<sup>(2)</sup> and/or [- blood and blood products originating from live animals that did not show clinical signs of any disease communicable through these products to humans or animals;]	
		<sup>(2)</sup> and/or [- material from animals which have been treated with certain substances which are prohibited pursuant to Directive 96/22/EC, the import of the material being permitted in accordance with Article 35(a)(ii) of Regulation (EC) No 1069/2009;]	
	II.4.	the blood from which such products are manufactured has been collected:	
		<sup>(2)</sup> either <del>[in slaughterhouses approved in accordance with Union legislation,]</del>	
		<sup>(2)</sup> or [in slaughterhouses approved and supervised by the competent authority of the third country,]	
		<sup>(2)</sup> or [from live animals in facilities approved and supervised by the competent authority of the third country.]	
	<sup>(2)</sup> [II.5.	In case of blood products derived from Artiodactyla, Perissodactyla and Proboscidea including their crossbreeds, other than Suidae and Tayassuidae, the products have undergone one of the following treatments, guaranteeing the absence of pathogens of foot-and-mouth disease, vesicular stomatitis, rinderpest, peste des petits ruminants, Rift Valley fever and bluetongue:	
		<sup>(2)</sup> either [heat treatment at a temperature of 65 °C for at least three hours, followed by an effectiveness check;]	
		<del><sup>(2)</sup>or [irradiation at 25 kGy by gamma rays, followed by an effectiveness check;]</del>	
		<del><sup>(2)</sup>or [change in pH to pH 5 for two hours, followed by an effectiveness check;]</del>	
		<del><sup>(2)</sup>or [heat treatment of at least 80 °C throughout their substance, followed by an effectiveness check.]]</del>	
	<sup>(2)</sup> [II.6.	<del>In the case of blood products derived from Suidae, Tayassuidae, poultry and other avian species, the products have undergone one of the following treatments guaranteeing the absence of pathogens of the following diseases: foot-and-mouth disease, vesicular stomatitis, swine vesicular disease, classical swine fever, African swine fever, Newcastle disease and highly pathogenic avian influenza as appropriate to the species:</del>	
		<del><sup>(2)</sup>either [heat treatment at a temperature of 65 °C for at least three hours, followed by an effectiveness check;]</del>	
		<del><sup>(2)</sup>or [irradiation at 25 kGy by gamma rays, followed by an effectiveness check;]</del>	
		<del><sup>(2)</sup>or [heat treatment of at least 80 °C for Suidae/Tayassuidae<sup>(2)</sup> and at least 70 °C for poultry and other avian species<sup>(2)</sup> throughout their substance, followed by an effectiveness check;].</del>	

